YOLFTbeta
General Biologicals Corporation

General Biologicals Corporation

4117 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

7.30TWD+0.10 (+1.39%)

Price History

Full chart

Market Stats

Previous Close7.20
Open7.13
Day Range7.12 – 7.60
52-Week Range3.50 – 17.30
Volume23.67K
Market Cap593.24M
P/E (TTM)1.00
Forward P/E0.00
EPS8.42
Dividend Yield0.00%
Beta0.57
50-Day Avg9.58
200-Day Avg8.79

About

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products under the oh care brand. Further, the company serves its diagnostic solutions through clinics and laboratories. General Biologicals Corporation was founded in 1984 and is headquartered in Hsinchu City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Frank Lin M.B.A.
  • HeadquartersNo. 6, Innovation First Road, Hsinchu City, Taiwan, 300092, Taiwan
  • Websitehttps://www.gbc.com.tw

Leadership

  • Mr. Frank Lin M.B.A.President & Director
  • Dr. C.M. LingFounder
  • Ming Shan LiuDeputy General Manager of Sales Marketing and Director

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue239.65M475.87M551.66M370.46M264.82M251.93M215.74M
Growth (%)-+98.57%+15.93%-32.85%-28.51%-4.87%-14.36%
Cost of Revenue112.81M224.81M269.72M198.61M202.12M244.39M156.12M
Gross Profit126.84M251.06M281.94M171.85M62.71M7.54M59.62M
Gross Margin52.93%52.76%51.11%46.39%23.68%2.99%27.63%
Operating Expense161.37M207.69M238.14M212.72M232.64M220.68M277.98M
Operating Income-34.53M43.37M43.79M-40.87M-169.94M-213.14M-218.37M
Operating Margin-14.41%9.11%7.94%-11.03%-64.17%-84.61%-101.22%
EBITDA-14.91M85.56M85.34M7.99M-139.06M-170.71M604.30M
EBITDA Margin-6.22%17.98%15.47%2.16%-52.51%-67.76%280.11%
Net Income-39.05M62.15M44.14M-53.19M-198.83M-220.82M465.84M
Net Income Margin-16.29%13.06%8.00%-14.36%-75.08%-87.65%215.93%
R&D35.81M41.13M34.24M35.85M33.11M49.53M64.55M
R&D as % of Total Revenue14.94%8.64%6.21%9.68%12.50%19.66%29.92%
Interest Expense4.68M3.32M11.00M16.86M11.98M13.37M19.73M
Interest Expense % of Total Revenue1.95%0.70%1.99%4.55%4.52%5.31%9.14%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets281.30M833.28M1.26B1.55B2.54B3.41B4.87B
Total Liabilities209.43M145.54M529.79M857.51M2.04B3.12B4.00B
Total Equity71.88M684.55M731.51M690.52M495.13M284.59M870.69M
Cash29.96M350.61M308.77M262.18M217.12M251.65M243.34M
Total Debt117.59M69.15M454.17M470.13M549.51M2.31B-
Net Debt87.63M-281.45M145.40M207.95M332.39M2.06B1.84B

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.75M46.74M38.97M225.01M225.68M-116.11M-127.26M
Investing Cash Flow1.95M-186.30M-75.76M-277.91M-342.31M-1.56B-
Financing Cash Flow-14.21M471.80M-4.26M-9.74M72.37M1.71B-
Capital Expenditure1.15M25.93M124.82M248.60M425.02M1.52B175.55M
Free Cash Flow-2.90M20.82M-85.85M-23.60M-199.33M-1.64B-302.81M
FCF to OCF165.58%44.53%-220.28%-10.49%-88.32%1411.02%237.94%

Key Statistics & Ratios

Market Cap593.24M
Enterprise Value2.51B
Trailing P/E1.00
Forward P/E0.00
Price / Sales2.28
Price / Book0.74
EPS8.42
Book Value11.25
Revenue (TTM)260.23M
Gross Profit (TTM)92.14M
EBITDA-56.87M
Profit Margin199.43%
Operating Margin-27.78%
Return on Equity108.50%
Return on Assets-2.08%
Shares Outstanding70.79M
Shares Float35.36M
Beta0.57
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%